CIK细胞联合白细胞介素-2对非小细胞肺癌患者免疫功能及生命质量的影响  

Effect of adoptive immunotherapy with CIK cells combined with interleukin-2 on immunologic function and life qualities of patients with non-small cell lung cancer

作　　者：薛鸣[1] 郭明坤[1] 

机构地区：[1]河南省新乡市中心医院放疗科,453000

出　　处：《国际肿瘤学杂志》2015年第2期88-90,共3页Journal of International Oncology

摘　　要：目的观察细胞因子诱导杀伤（CIK）细胞联合白细胞介素-2（IL=2）对非小细胞肺癌（NSCLC）患者免疫功能及生命质量的影响。方法将符合条件的38例患者按相似条件配对分为两组。治疗组患者放化疗后接受CIK细胞联合IL-2治疗，对照组仅行放化疗。观察CIK细胞回输后患者的不良反应及生命质量改善情况。取两组患者放化疗结束时（CIK细胞治疗前）及放化疗结束后3个月（CIK细胞治疗已结束）两个时间点，分别观察治疗组和对照组患者免疫指标（外周血CD3^＋、CD4^＋、CD8^＋T细胞百分比，CD4^＋／CD8^＋及Th1／Th2比值）。结果治疗过程中未出现明显不良反应，治疗组19例患者经CIK细胞联合IL-2治疗后精神改善者18例，食欲改善者15例，睡眠改善者12例，疲乏症状改善者3例。治疗组患者CD3^＋、CD4^＋T细胞百分比升高[（66．39±9．22）％：（42．98±7．23）％，t=5．45，P=0．00；（32．27±3．75）％：（26．38±2．51）％，t=5．73，P=0．00]，CD8^＋T细胞百分比降低[（17．51±1．85）％：（20．90±2．31）％，t=5．21，P=0．00]，CD4^＋／CD8^＋比值上调、Th1／Th2正置[（1．86±0．32）：（1．27±0．19），t=7．13，P=0．00；（1．15±0．48）：（0．91±0．30），t=2．42，P=0．02]，与对照组比较差异均有统计学意义。结论CIK细胞联合IL-2治疗可改善NSCLC患者免疫功能，并在一定程度上改善患者的生命质量，且无明显不良反应。Objective To investigate the changes of immunologic functions and life qualities after the auto-cytokine induced killer （ CIK ） cells combined with interleukin-2 （ IL-2 ） being transfused back to the patients with non-small cell lung cancer （NSCLC）. Methods Thirty-eight NSCLC patients were enrolled, and 19 patients received not only chemotherapy and radiotherapy but also adoptive immunotherapy with CIK ceils combined with IL-2 compared with the other 19 patients who only accepted radiotherapy and chemotherapy. The changes of immunologic functions and life qualities after the CIK cells combined with IL-2 being transfused back to the patients with NSCLC were observed. Immune targets of the treatment group and control group, such as peripheral blood CD3^＋, CD4^＋, CD8^＋ T cell percentage, ratio of CD4^＋/CD8^＋ and Th1/Th2, were observed at the end and after 3 month of the radiation and chemotherapy. Results Both of the two groups were neither having obvious adverse reactions. After CIK cells combined with IL-2 treatment, the life qualities of patients improved, such as 18 cases of mental improvement, 15 cases of appetite improvement, 12 cases of sleep improvement, and 3 cases of fatigue symptoms improvement. The percentage of CD3^＋, CD4^＋ cells in the treatment group increased [（66.39±9.22）% vs （42.98±7.23）%, t=5.45,P=0.00;（32.27±3.75）% vs （26.38±2.51 （20.90±2.31 [（1.86±0.32 %, t =5.73,P =0.00], the percentage of CD8- cells declined [（17.51±1.85）% vs % , t = 5.21 ,P = 0.00 ] , the rate of CD4^＋/CD8^＋ increased and the rate of Th1/Th2 obversed vs （1.27±0.19）, t=7.13,P=0.00;（1.15±0.48） vs （0.91±0.30）, t=2.42,P= 0.02 ]. There were significant differences between the two groups. Conclusion Adoptive immunotherapy with CIK cells combined with IL-2 is safe in clinical, which can improve the immunologic functions and life qualities of the patients with NSCLC.

关 键 词：癌 非小细胞肺 免疫疗法 细胞因子诱导杀伤细胞 

分 类 号：R734.2[医药卫生—肿瘤]